Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Medical College of Nantong University, Nantong, Jiangsu, China.
Pathol Res Pract. 2020 Apr;216(4):152850. doi: 10.1016/j.prp.2020.152850. Epub 2020 Feb 5.
Hepatocellular carcinoma (HCC) is an aggressive malignant tumor with poor prognosis that is characterized by high rates of postoperative recurrence and mortality. Understanding the molecular mechanism of this malignancy is of great significance for the development of new and effective strategies for the treatment of hepatocellular carcinoma. Thyroid hormone receptor-interacting protein 6 (TRIP6), also known as zyxin-related protein-1 or ZRP-1, is an adaptor protein that belongs to the zyxin family of LIM proteins. Recent studies showed that TRIP6 is involved in carcinogenesis. But the functional role of TRIP6 in HCC has not been reported to date.
TRIP6 expression level in HCC cell lines and normal cell line was measured by qPCR. The roles of TRIP6 on HCC cell proliferation, colony formation, and invasion were examined by MTT assay, colony formation assay, and transwell invasion assay, respectively. The effect of TRIP6 on the overall survival of HCC patients was further analyzed. ChIP assay and western blot were performed to validate whether FOXC1 was involved in the regulation of TRIP6 expression.
Western blot and immunohistochemical analyses showed that TRIP6 expression was up-regulated in HCC tissues compared with adjacent non-tumor tissues. Kaplan-Meier survival analysis indicated that upregulation of TRIP6 was dramatically associated with poor overall survival. TRIP6 knockdown significantly inhibited cell migration, invasion, and proliferation, and its effect on cell proliferation was mediated by the modulation of cell cycle progression. FOXC1 also played a vital role in TRIP6 regulation. TRIP6 mediated the FOXC1-regulated proliferation, invasion, and migration in vitro and tumor growth in vivo.
These results suggest that TRIP6 may contribute to the invasiveness and metastasis of HCC cells, and provide new insight into the crucial role of TRIP6 in tumorigenesis and cancer progression.
肝细胞癌(HCC)是一种侵袭性恶性肿瘤,预后差,其特征是术后复发率和死亡率高。了解这种恶性肿瘤的分子机制对于开发新的有效治疗肝细胞癌的策略具有重要意义。甲状腺激素受体相互作用蛋白 6(TRIP6),也称为 zyxin 相关蛋白-1 或 ZRP-1,是一种衔接蛋白,属于 zyxin 家族的 LIM 蛋白。最近的研究表明,TRIP6 参与了癌症的发生。但迄今为止,TRIP6 在 HCC 中的功能作用尚未报道。
通过 qPCR 测量 HCC 细胞系和正常细胞系中 TRIP6 的表达水平。通过 MTT 测定、集落形成测定和 Transwell 侵袭测定分别检测 TRIP6 对 HCC 细胞增殖、集落形成和侵袭的作用。进一步分析 TRIP6 对 HCC 患者总生存率的影响。进行 ChIP 测定和 Western blot 以验证 FOXC1 是否参与 TRIP6 表达的调节。
Western blot 和免疫组织化学分析表明,与相邻非肿瘤组织相比,TRIP6 在 HCC 组织中表达上调。Kaplan-Meier 生存分析表明,TRIP6 的上调与总生存率显著相关。TRIP6 敲低显著抑制细胞迁移、侵袭和增殖,其对细胞增殖的影响是通过细胞周期进程的调节介导的。FOXC1 也在 TRIP6 调节中发挥了重要作用。TRIP6 在体外介导了 FOXC1 调节的增殖、侵袭和迁移以及体内肿瘤生长。
这些结果表明,TRIP6 可能有助于 HCC 细胞的侵袭和转移,并为 TRIP6 在肿瘤发生和癌症进展中的关键作用提供了新的见解。